Beta blockers in the management of chronic kidney disease (Q36614867)

15 August 2017

1 reference

title

Beta blockers in the management of chronic kidney disease (English)

1 reference

15 August 2017

Bakris GL

1

1 reference

15 August 2017

Hart P

series ordinal

2

1 reference

15 August 2017

Ritz E

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

4 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

70

1 reference

15 August 2017

11

1 reference

15 August 2017

1905-1913

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001835

15 August 2017

0 references

cites work

Neural control of the kidney: past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Neurogenic factors in renal hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal afferent denervation prevents hypertension in rats with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Moxonidine treatment of hypertensive patients with advanced renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Microvascular disease--the Cinderella of uraemic heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Nephrologists neglect administration of betablockers to dialysed diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Diminished vascular response to noradrenaline in experimental chronic uremia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Sympathetic overactivity in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Sympathetic nerve activity in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Drug therapy for hypertension in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Role for $beta;-blockers in the management of diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Incident acute coronary syndromes in chronic dialysis patients in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Acute myocardial infarction and renal dysfunction: a high-risk combination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effects of labetalol and methyldopa on renal function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal haemodynamics after chronic treatment with labetalol and propranolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Catecholamine modulation of rapid potassium shifts during exercise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Dietary glutathione protects rats from diabetic nephropathy and neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal effects of antihypertensive medications: an overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Acute renal effects of beta-blockers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Treatment with atenolol prevents progression of microalbuminuria in Type I diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The pharmacokinetics of metoprolol and its metabolites in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Supervised atenolol therapy in the management of hemodialysis hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Pharmacokinetics of atenolol in relation to renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Renal protective effect of enalapril in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The long-term effect of propranolol therapy on renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Endocrine and Metabolic Effects of Labetalol in Man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The disposition and dynamics of labetalol in patients on dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Labetalol-induced hyperkalemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Cardiac adrenergic receptor effects of carvedilol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effect of long-term carvedilol therapy on renal function in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Chronic renal insufficiency: a diagnostic and therapeutic approach.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Microalbuminuria and oxidative stress in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Nebivolol in the management of essential hypertension: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001835

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001835

1 reference

15 August 2017

1 reference